FDA asks Possis for AngioJet trial details:
This article was originally published in Clinica
The FDA has asked Possis Medical to supply more details on the statistical methods used in the clinical trials of its AngioJet Rapid Thrombectomy System. The system was submitted for a 510(k) clearance in July and is designed to removed blood clots from vessels throughout the body. Possis is expecting to provide this extra information by mid-November and hopes the FDA will respond within 90 days of its submission.
You may also be interested in...
Perrigo, Pfizer want the US FDA to postpone its March 1 deadline for conducting nitrosamine risk assessments. Generics exec cites“serious compliance challenges” in conducting these assessments due to difficulty in finding the right lab equipment necessary to quantify nitrosamine daily intake limits.
Deal snapshot: For $425m up front, the pharma obtains a Phase III recombination fusion protein that shows ability to improve hospitalized patients’ clinical status and reduce risk of death.
Previous businesses FDA warned about COVID-19 claims for chlorine dioxide, a bleach solution, were marketing dietary supplements unlawfully. But Pro Breath MD's oral rinses available under the Dentist Select and OraCare brands are allowed and FDA isn’t asking the firm to discontinue distribution.